Veeva Systems (NYSE:VEEV) Rating Lowered to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Veeva Systems from “Buy” to “Hold,” though broader analyst sentiment remains positive with a “Moderate Buy” consensus and an average price target of $284.88.
• Veeva exceeded quarterly expectations, reporting $2.35 in EPS and $927.96 million in revenue, up 17.6% year over year. Shares opened at $280.95, near the consensus target but below the 52-week high of $310.50.
• Insiders sold 46,750 shares worth approximately $12.0 million during the quarter, while institutional investors continued to hold a substantial 88.2% of the company’s stock.

Veeva Systems (NYSE:VEEV - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

A number of other equities research analysts have also issued reports on VEEV. Morgan Stanley increased their target price on Veeva Systems from $215.00 to $275.00 and gave the company an "equal weight" rating in a research note on Thursday, August 27th. Raymond James Financial restated an "outperform" rating and issued a $225.00 price target on shares of Veeva Systems in a report on Thursday, June 4th. Truist Financial increased their price objective on shares of Veeva Systems from $262.00 to $305.00 and gave the company a "buy" rating in a research report on Thursday, August 27th. Oppenheimer lifted their price objective on shares of Veeva Systems from $225.00 to $300.00 and gave the company an "outperform" rating in a research note on Monday, August 17th. Finally, Guggenheim boosted their target price on shares of Veeva Systems from $276.00 to $310.00 and gave the stock a "buy" rating in a research report on Thursday, August 27th. Nineteen equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Veeva Systems has an average rating of "Moderate Buy" and an average target price of $284.88.

Veeva Systems Stock Up 2.2%

Veeva Systems stock opened at $280.95 on Friday. The firm has a fifty day moving average of $243.35 and a 200-day moving average of $196.79. Veeva Systems has a 52-week low of $148.05 and a 52-week high of $310.50. The firm has a market capitalization of $45.49 billion, a P/E ratio of 46.21, a PEG ratio of 1.17 and a beta of 0.97.

Veeva Systems (NYSE:VEEV - Get Free Report) last announced its quarterly earnings results on Wednesday, August 26th. The technology company reported $2.35 earnings per share for the quarter, topping analysts' consensus estimates of $2.23 by $0.12. Veeva Systems had a net margin of 29.34% and a return on equity of 14.25%. The firm had revenue of $927.96 million during the quarter, compared to analysts' expectations of $905.38 million. During the same period in the prior year, the company earned $1.99 EPS. The firm's revenue was up 17.6% on a year-over-year basis. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. On average, research analysts expect that Veeva Systems will post 6.7 EPS for the current fiscal year.

Insider Activity at Veeva Systems

In other news, Director Priscilla Hung sold 750 shares of the firm's stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $261.04, for a total transaction of $195,780.00. Following the completion of the sale, the director owned 3,242 shares of the company's stock, valued at approximately $846,291.68. This trade represents a 18.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Thomas Schwenger sold 36,000 shares of Veeva Systems stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $250.23, for a total transaction of $9,008,280.00. Following the completion of the sale, the insider owned 19,449 shares of the company's stock, valued at approximately $4,866,723.27. This trade represents a 64.92% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 46,750 shares of company stock valued at $12,017,360. Company insiders own 10.60% of the company's stock.

Institutional Investors Weigh In On Veeva Systems

Several hedge funds and other institutional investors have recently modified their holdings of the stock. SHP Wealth Management bought a new position in shares of Veeva Systems during the fourth quarter worth about $26,000. MV Capital Management Inc. bought a new stake in Veeva Systems in the fourth quarter valued at about $30,000. Reflection Asset Management acquired a new stake in Veeva Systems during the fourth quarter valued at approximately $32,000. Compass Financial Management LLC acquired a new stake in Veeva Systems during the second quarter valued at approximately $27,000. Finally, Arlington Trust Co LLC bought a new position in Veeva Systems during the 2nd quarter worth approximately $29,000. Institutional investors own 88.20% of the company's stock.

More Veeva Systems News

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: AI product launch could improve growth and customer value. Veeva Study Builder Agent can configure Veeva EDC and Data Quality System directly from a clinical-study protocol, potentially reducing manual setup work and enabling studies to be configured in as little as one day. The tool uses customer standards and the CDISC Unified Study Definitions Model to produce faster, more consistent builds. New Veeva Study Builder Agent to Configure Clinical Studies in as Little as One Day
• Positive Sentiment: Recent customer wins support the platform’s competitive position. Oxford Biomedica is adopting Veeva Quality Cloud, while Amgen plans a global deployment of Veeva Vault CRM. These agreements expand Veeva’s presence with large biopharmaceutical customers and could support recurring revenue and cross-selling. How Investors Are Reacting To Veeva Systems Expanding Agentic AI And Winning New Pharma Clients
• Positive Sentiment: Analysts see potential valuation upside. One recent assessment argued that VEEV could be approximately 29% undervalued following the Study Builder Agent launch, suggesting investors may not yet fully reflect the commercial potential of its AI initiatives. Veeva Systems Could Be 29% Undervalued Following Its New AI Study Design Launch
• Neutral Sentiment: Industry growth provides a favorable backdrop. The quality-management software market is projected to grow at an approximately 11.7% annual rate through 2031, potentially expanding Veeva’s addressable market, although the forecast is not company-specific. Quality Management System Software Market Forecasts Growth
• Negative Sentiment: Near-term performance remains a concern. VEEV has declined 2.6% since its latest earnings report, indicating that investors may be seeking stronger forward guidance or additional evidence that AI investments will accelerate results. The stock also trades at a premium valuation, increasing sensitivity to estimates and execution. Veeva Down 2.6% Since Last Earnings Report

About Veeva Systems

Veeva Systems Inc is a cloud software company that provides technology solutions for the life sciences industry, including pharmaceutical, biotechnology, medical device and related organizations. Its applications are designed to support functions across the product lifecycle, from research and clinical development through regulatory approval, manufacturing, quality management and commercial operations.

The company's Veeva Vault platform includes applications for clinical data management, electronic trial management, regulatory information, quality processes, safety operations and commercial content management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.